Home
Team
Blog
Experts
Careers
Projects
Code of Conduct
Press
Publications
Contact Us
Topics:
Breast Cancer
•
Medical Oncology
•
Her2+
•
HR+
What adjuvant chemotherapy would you recommend for a postmenopausal woman with history of porphyria and newly diagnosed T2 N0 triple positive breast cancer?
Related Questions
Is there a role for extended adjuvant neratinib with pCR after neoadjuvant chemotherapy in triple positive breast cancer?
Would you give a HER2 targeted agent to a patient whose initial cancer was ER/PR positive, HER2 negative but now with metastatic disease that is ER positive, PR negative, HER2 2+, FISH equivocal?
How would you modify adjuvant therapy for a patient with ER+ HER2+ breast CA with no response to neoadjuvant TCHP and develops pneumonitis on adjuvant TDM-1?
Do you give adjuvant chemotherapy/trastuzumab to a premenopausal woman with a pT1aN0 HR+, Her2+ breast cancer?
How would you manage a patient with early stage ER+ HER2+ breast CA who cannot receive definitive local therapy due to severe cardiopulmonary co-morbidities?
How would you treat HR positive, HER2 positive metastatic breast cancer in patients with a borderline or poor performance status?
How would you manage adjuvant therapy for a premenopausal female with a T1cN1mi breast IDC that is HR+ HER2 positive on biopsy, but HR+ HER2 negative on lumpectomy surgical specimen?
How long would you keep a patient on endocrine/dual anti HER-2 therapy after resection of a late (>5 years) oligometastatic recurrence of ER+ HER2+ breast CA?
What adjuvant systemic therapy would you offer to a healthy elderly woman with a 5mm, node negative, grade 2 HR+HER2+ invasive lobular carcinoma?
In what situations would you offer systemic therapy for HER2+ microinvasive invasive ductal carcinoma?
